Cargando…

The association between US Food and Drug Administration−expedited review designations and health plan specialty drug coverage

BACKGROUND: The US Food and Drug Administration (FDA) speeds approval of important clinical advancements through 4 expedited review programs: Priority Review, Accelerated Approval, Fast Track, and Breakthrough Therapy. Whether health plans prioritize coverage of expedited drugs relative to drugs tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panzer, Ari D, Ingham, Michael, Martin, Silas, Chambers, James D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394180/ https://www.ncbi.nlm.nih.gov/pubmed/36989444 http://dx.doi.org/10.18553/jmcp.2023.22415

Ejemplares similares

Variation in health plan specialty drug coverage: an empirical analysis
por: Margaretos, Nikoletta M., et al.
Publicado: (2019)

Examining US commercial health plans’ use of The Institute for Clinical and Economic Review’s reports in specialty drug coverage decisions
por: Chambers, James D, et al.
Publicado: (2023)

Limited role of patient input in specialty drug coverage policies
por: D’Cruz, Brittany, et al.
Publicado: (2021)

Specialty drug coverage varies between health plans’ medical and pharmacy benefit policies
por: Levine, A. Alex, et al.
Publicado: (2023)

Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration–expedited programs
por: Jenkins, Nola B, et al.
Publicado: (2023)

Expedited Development Programs at the Food and Drug Administration: Insights and Opportunities
por: Collins, Grace, et al.
Publicado: (2021)

Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021
por: Monge, Andrea N., et al.
Publicado: (2022)

Use of prescriber requirements among US commercial health plans
por: Lenahan, Kelly, et al.
Publicado: (2021)

Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017
por: Zhu, Xingyue, et al.
Publicado: (2022)

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Time From Authorization by the US Food and Drug Administration to Medicare Coverage for Novel Technologies
por: Sexton, Zachary A., et al.
Publicado: (2023)

Cryptosporidiosis should be designated as a tropical disease by the US Food and Drug Administration
por: Choy, Robert K. M., et al.
Publicado: (2020)

Variation in health plan coverage of ESAs for anemia due to chronic kidney disease
por: Margaretos, NikoLetta M, et al.
Publicado: (2021)

Cyberpharmacies and the role of the US Food And Drug Administration
por: Henney, Jane E
Publicado: (2001)

The US Food and Drug Administration’s Intersection with Dermatology
por: Luke, Markham C.
Publicado: (2022)

Specialty and cancer drugs set to drive US drug expenditure in 2021
Publicado: (2021)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
por: Marchand, Heidi C., et al.
Publicado: (2012)

Assessment of Public Opinion on Transparency at the US Food and Drug Administration
por: Azad, Tej D., et al.
Publicado: (2022)

US food and drug administration Indian site inspections: An experience
por: Mahajan, Pooja, et al.
Publicado: (2012)

Characterizing health plan evidence review practices
por: Panzer, Ari D, et al.
Publicado: (2022)

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

Review of Evidence Supporting 2022 US Food and Drug Administration Drug Approvals
por: Kaplan, Robert M., et al.
Publicado: (2023)

30 years of media coverage on high drug prices in the US – a never-ending story or a time for change?
por: Leopold, Christine, et al.
Publicado: (2015)

Health Plan Utilization and Costs of Specialty Drugs Within 4 Chronic Conditions
por: Gleason, Patrick P., et al.
Publicado: (2013)

US Food and Drug Administration regulatory updates in neuro-oncology
por: Mehta, Gautam U., et al.
Publicado: (2021)

The Significance of Information Posted on the U.S. Food and Drug Administration’s Website
por: Cook, G. Elliott, et al.
Publicado: (2013)

Health Plan Approach to Operationalizing a Specialty Drug Management Program
por: Tegenu, Mesfin
Publicado: (2008)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2021)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2022)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2023)

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
por: Parikh, Ravi B., et al.
Publicado: (2023)

Expedited drug review process: Fast, but flawed
por: Chary, Krishnan Vengadaraga
Publicado: (2016)

FDA expedited approval and implications for rational formulary and health plan design
por: Ferries, Erin A, et al.
Publicado: (2021)

Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs
por: Chambers, James D., et al.
Publicado: (2016)

Vaccines, pharmaceutical products, and bioterrorism: challenges for the U.S. Food and Drug Administration.
por: Zoon, K C
Publicado: (1999)

The clinical pharmacogeneticist: An emerging regulatory scientist at the US Food and Drug Administration
por: Zineh, Issam, et al.
Publicado: (2010)

Why the Watchdog Won’t Bite: U.S. Food and Drug Administration Challenges
por: Lex, Joe
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hvjabhtpl1p0c2g6s2odnoeq53